Alder biopharmaceuticals inc (ALDR)
CashFlow / Quarterly
Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities
Net loss

-58,411

-117,934

-80,089

-60,920

-68,389

-87,031

-54,357

-59,565

-74,629

-100,328

-48,891

-35,134

-38,866

-33,363

-26,165

-26,997

-17,655

-14,653

-6,942

28,646

-7,401

-5,395

-3,875

-5,909

-5,147

-5,682

Adjustments to reconcile net loss to net cash used in operating activities
Equity in net loss of unconsolidated entity

-

-

0

0

0

-222

-180

-184

-130

-149

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

537

533

422

537

807

801

763

752

739

747

660

509

270

235

180

186

190

195

174

172

167

188

227

235

232

241

Loss on retirement of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-2

-

-

-

-

-

-

-

-

Stock-based compensation

11,671

6,288

5,848

6,403

7,223

5,946

5,776

5,821

5,721

5,180

4,098

3,511

3,331

3,017

2,015

1,818

1,396

910

492

370

240

148

142

140

134

159

Accretion of discount on convertible notes

3,177

3,042

3,066

2,986

2,855

1,689

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash change in fair value of derivative liability

-125

-975

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-cash charges, net

983

729

768

914

855

605

324

143

-121

-179

-185

-157

-45

-20

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities
Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-113

32

24

-34

-225

218

-35

-23

28

Prepaid expenses and other assets

7,214

-3,652

797

-998

360

-3,733

-6,576

-3,631

1,394

-28,553

17,110

14,555

169

-460

278

2,980

2,322

4,164

113

2,928

2,881

-726

-90

-1,343

-319

699

Accounts payable

-7,649

6,392

-6,913

160

2,710

5,316

-14,907

2,675

-504

10,341

4,520

-1,883

-2,070

4,921

-3,006

5,379

138

305

227

-987

966

-518

1,101

480

-1,318

40

Accrued liabilities

-596

23,205

6,389

-892

2,080

-4,163

-210

1,777

4,993

-6,194

4,554

3,178

2,668

-2,557

607

2,537

-146

1,275

491

895

-255

-296

-1,104

882

942

-578

Deferred rent

-

-

-8

15

-7

-3

41

31

-32

-26

361

-16

42

-14

-28

-33

-35

-32

-17

114

116

63

-9

-37

-42

-41

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,323

-38,703

-4,603

-4,695

-4,493

-4,646

-4,580

-4,534

Net cash used in operating activities

-59,298

-74,576

-72,850

-51,474

-52,431

-74,095

-55,526

-44,837

-64,855

-61,399

-51,532

-44,139

-36,735

-27,281

-26,667

-20,083

-18,434

-16,049

-12,041

-12,445

-13,617

-9,554

-8,139

-7,474

-9,397

-11,122

Investing activities
Purchases of investments

0

64,022

0

35,764

71,828

415,203

61,718

215,488

0

28,334

31,845

78,413

49,047

6,566

5,129

160,750

7,000

12,750

-

-

-

-

-

-

-

-

Proceeds from maturities of investments

29,000

36,290

62,000

66,629

37,000

156,000

106,229

68,617

112,965

54,008

29,070

65,445

4,000

6,250

4,230

6,965

6,915

1,225

-

-

-

-

735

1,455

3,185

245

Proceeds from sales of investments

-

-

0

0

0

83,184

-

-

-

-

-

-

-

-

0

0

0

250

-

-

-

-

-

-

-

-

Purchases of property and equipment

736

303

1,799

1,060

65

212

54

470

677

849

1,057

2,609

2,022

931

501

76

271

375

241

96

292

20

78

23

43

49

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

0

0

0

5

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

28,264

-28,035

60,201

29,805

-34,893

-176,231

44,457

-147,190

112,288

24,825

-3,832

-15,577

-47,069

-1,242

-1,400

-153,861

-356

-11,650

720

-97

-10,337

-20

657

1,551

3,142

196

Financing activities
Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-36

-

-

-

756

-

-

-

0

Proceeds from issuance of 2025 convertible senior notes, net of offering costs

-

-

0

0

0

277,656

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of offering costs

-

-

0

0

0

97,710

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of offering costs

-209

159,307

-

-

-

-

-

-

-

-

-

-

-

-

0

-190

216,054

190,770

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and employee stock purchase plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

541

167

806

22

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

430

-

-

-

20

-

-

643

71

-

-

-

45

-

-

-

-

-

-

-

34

-

0

0

16

Net cash provided by financing activities

762

159,737

1,104

325

1,122

375,386

631

161,572

643

71

948

312

135,805

45

541

-23

216,860

190,828

589

-154

81,269

-722

32

0

0

16

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

0

0

0

21

11

8

-14

-14

-26

-8

4

7

13

6

-4

-3

Net increase in cash, cash equivalents and restricted cash

-30,272

57,126

-11,545

-21,344

-86,202

125,060

-10,438

-30,455

48,076

-36,503

-54,416

-59,404

52,001

-28,457

-27,515

-173,959

198,056

163,115

-10,758

-12,704

57,319

-10,289

-7,437

-5,917

-6,259

-10,913

Supplemental disclosures:
Cash paid for interest

0

3,594

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs included in accounts payable and accrued liabilities

-

265

-

-

-

-

-

-

-

-

-

-

-

-

-

-

94

25

-

-160

-308

560

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued liabilities

55

188

-341

304

224

22

-132

39

0

101

69

-722

968

188

-

-

-

-

-

-

-

-

-

-

-

-